ShanghaiTech University Knowledge Management System
Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method | |
2022-02-05 | |
发表期刊 | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (IF:3.1[JCR-2023],3.1[5-Year]) |
ISSN | 0731-7085 |
EISSN | 1873-264X |
卷号 | 209 |
发表状态 | 已发表 |
DOI | 10.1016/j.jpba.2021.114538 |
摘要 | The 3C-like protease (3CLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential to the virus life cycle and is supposed to be a potential target for the treatment of coronaviral infection. Traditional Chinese medicines (TCMs) have played an impressive role in the treatment of COVID-19 in China. The effectiveness of TCM formulations prompts scientists to take continuous effort on searching for bioactive small molecules from the ancient resources. Herein, we developed a native mass spectrometry-based affinity-selection method for rapid screening of active small molecules from crude herbal extracts applied for COVID-19 therapy. Six common herbs named Lonicera japonica, Scutellaria baicalensis, Forsythia suspensa, Glycyrrhiza uralensis, Cirsium japonicum, and Andrographis paniculata were investigated. After preliminary separation of the crude extracts, the fractions were incubated with 3CLpro. A native MS-based affinity screening assay was then conducted to search for the protein-ligand complexes. A UHPLC-Q/TOF-MS with UNIFI data acquisition and data processing software was applied to identify the hit compounds. Standard compounds were used to verify the outcomes. Among the 16 hits, three flavonoids, baicalein, scutellarein and ganhuangenin, were identified as potential noncovalent inhibitors against 3CLpro with IC values of 1.14, 3.04, and 0.84 μM, respectively. Their binding affinities were further characterized by native MS, with K values being 1.43, 3.85, and 1.09 μM, respectively. Overall, we established an efficient native MS-based strategy for discovering 3CLpro ligands from crude mixtures, which supplies a potential strategy of small molecule lead discovery from TCMs. |
关键词 | 3CL protease Native MS Natural product SARS-CoV-2 Traditional Chinese medicine |
URL | 查看原文 |
收录类别 | SCIE |
语种 | 英语 |
Scopus 记录号 | 2-s2.0-85121216788 |
来源库 | Scopus |
引用统计 | 正在获取...
|
文献类型 | 期刊论文 |
条目标识符 | https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/139004 |
专题 | 生命科学与技术学院_博士生 生命科学与技术学院_特聘教授组_叶阳组 |
通讯作者 | Xu,Yechun |
作者单位 | 1.School of Life Science and Technology,ShanghaiTech University,Shanghai,201203,China 2.State Key Laboratory of Drug Research,and Natural Products Chemistry Department,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China 3.University of Chinese Academy of Sciences,Beijing,100049,China 4.CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China 5.Bruker Daltonik GmbH,Bremen,28359,Germany 6.Griffith Institute for Drug Discovery,Griffith University,Brisbane,4111,Australia 7.Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China 8.School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,University of Chinese Academy of Sciences,Hangzhou,310058,China |
第一作者单位 | 生命科学与技术学院 |
第一作者的第一单位 | 生命科学与技术学院 |
推荐引用方式 GB/T 7714 | Zhu,Dafu,Su,Haixia,Ke,Changqiang,et al. Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method[J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,2022,209. |
APA | Zhu,Dafu.,Su,Haixia.,Ke,Changqiang.,Tang,Chunping.,Witt,Matthias.,...&Ye,Yang.(2022).Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method.JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS,209. |
MLA | Zhu,Dafu,et al."Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method".JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 209(2022). |
条目包含的文件 | ||||||
文件名称/大小 | 文献类型 | 版本类型 | 开放类型 | 使用许可 |
修改评论
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。